GLPwatch
Papers (10386)
Page 133 of 174, ranked by citation count.
- Consumer group calls for antidiabetes drug to be withdrawn.
- Incretins and amylin in pediatric diabetes: new tools for management of diabetes in youth.
- Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial.
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
- Rhabdomyolysis triggered by initiation of tirzepatide.
- Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
- Efficacy and tolerability of liraglutide in combination with other antidiabetic drugs in type 2 diabetes.
- Ozempic <i>v</i> Mounjaro: what is the difference between semaglutide and tirzepatide?
- Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic.
- Semaglutide vs Tirzepatide Dosages for Weight Loss.
- Exenatide once weekly: opportunities in the primary care setting.
- Case Report: Liraglutide for Weight Management in Beckwith-Wiedemann Syndromic Obesity.
- Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives.
- The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors.
- Dulaglutide for erectile dysfunction in type 2 diabetes.
- A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease.
- Neurological outcomes of antidiabetic therapy: What the neurologist should know.
- Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh.
- Multi-database pharmacovigilance assessment of GLP-1 receptor agonist-related ophthalmic risks using advanced signal detection in FAERS and vigibase.
- Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
- Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
- Therapeutic Function of Liraglutide for Mitigation of Blast-Induced Hearing Damage: An Initial Investigation in Animal Model of Chinchilla.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
- Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity.
- Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide.
- Cardiovascular safety of liraglutide for the treatment of type 2 diabetes.
- Early onset of acute pancreatitis in a patient on low-dose liraglutide.
- GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia.
- A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.
- Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.
- [Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].
- Diabetes: Cardiovascular benefits of semaglutide.
- Very-low calorie diet and Semaglutide: Synergy and long-term impact on type 2 diabetes management.
- Is liraglutide a useful addition to diabetes therapy?
- Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
- In adults with BMI ≥27 kg/m<sup>2</sup> and type 2 diabetes, adding tirzepatide to a lifestyle intervention increased weight loss at 72 wk.
- Semaglutide: FDA publishes warning amid reports of patients overdosing.
- The mechanism of glucagon-like peptide-1 participation in the osmotic homeostasis.
- The efficacy and safety of dual GIP/GLP1 receptor agonists (tirzepatide) in diabetes and obesity: a systematic review and network meta-analysis.
- Tirzepatide Affect Sexual Function in Women: Case Report.
- A call to update anesthetic protocols: the hidden risks of semaglutide.
- Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?
- A microporous liraglutide-releasing silk fibroin scaffold improves islet transplantation outcomes through anti-inflammatory effect.
- Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review.
- More on Semaglutide in Early Type 1 Diabetes.
- The cost-utility and budget impact analyses of Tirzepatide versus once-weekly Semaglutide as add-on therapy to metformin in patients with type 2 diabetes mellitus in China.
- Tirzepatide: A Breakthrough Therapy for Obstructive Sleep Apnea and Metabolic Dysfunction.
- Semaglutide in NASH-related cirrhosis: still a long way to go? - Authors' reply.
- A case report of severe adverse reaction of exenatide: Anaphylactic shock.
- Exendin-4 effects on islet volume and number in the mouse pancreas.
- REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: Ambispective, multicenter clinical study. Results in the GLP1-experienced cohort.
- Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study.
- Reduced incretin receptor trafficking upon activation enhances glycemic control and reverses obesity in diet-induced obese mice.
- Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).
- AI-Driven De Novo Design of Ultra Long-Acting GLP-1 Receptor Agonists.
- Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss.
- Gastrointestinal adverse events of semaglutide in patients with overweight or obesity.
- Characterisation of real-world patients who discontinued a glucagon-like peptide-1 agonist.
- Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
- Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application.